EGFR and neoplasm: Given the known and potentially confounding effects of cetuximab in inhibiting EGFR+ HNSCC tumor cell viability and in sensitizing these cells to radiation (7, 8, 10), we are not aware of any alternative syngeneic HNSCC model that would allow for testing of the interaction between radiation and cetuximab-mediated ADCC.